WCLC 2025: Latest in EGFR positive NSCLC
Dr Fernandez speaks with ecancer at the Best of ASCO meeting in Miami, to discuss new treatments for acute myeloid leukaemia and lymphoid leukaemia that have stemmed from molecular studies.
He discusses trials and new agents, alongside new immunotherapies.
My presentation today is on the new treatments for acute myeloid and lymphoid leukaemias. I am focussing on the new molecular studies that have been done and the trials and new agents that are used to treat these diseases. Initially we had chemotherapy as the only modality, now we have targeted molecular trials to treat these patients. We also have new immunotherapy available to treat these patients and I’ll be presenting about that today.
WCLC 2025: Latest in EGFR positive NSCLC
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Key insights from lung cancer research at ASCO 2025
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas